論文報告

研究発表実績

大阪医療センター 中谷 綾 Leuk Res Rep.2023 Nov 17:20:100395.

Impact of cytogenetic abnormalities in symptomatic multiple myeloma;a Japanese real-world analysis from Kansai Myeloma ...
研究発表実績

京都府立医科大学 志村勇司 Int Hematol. 2023 Nov;118(5):609-617.

Real-world data of induction therapies for patients with transplant-ineligible newly diagnosed multiple myeloma:Retrosp...
研究発表実績

京都大学 島津 裕 Sci Rep.2023 Mar 29;13(1):5159.

Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobuli...
研究発表実績

京都大学 島津 裕 Ther Adv Hematol.2022 Dec 13;13:20406207221142487.

Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide
研究発表実績

京都大学 恩田佳幸 Ther Adv Hematol.2022 Jun 24;13:20406207221104584.

Real-world effectiveness and safety analysis of carfilzomib-lenalidomide-dexamethasone andcarfilzomib-dexamethasone in ...
研究発表実績

大阪医療センター 中谷 綾 EJHaem. 2021 Oct 20;2(4):765-773.

Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma:A multicenter retrospective analysis...
研究発表実績

大阪市立大学 高桑輝人 Hematol Oncol. 2021 Aug;39(3):349-357.

Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma
研究発表実績

大阪市立大学 高桑輝人 Eur J Haematol. 2021 Apr;106(4):555-562.

Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis
研究発表実績

関西医科大学 中谷 綾 Int Hematol. 2020 Nov;112(5):666-673.

Retrospective analysis of plasmacytoma in Kansai Myeloma Forum registry
研究発表実績

関西医科大学 中谷 綾 Int Hematol. 2020 Oct;112(4):435-438.

Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myelomain Kansai Myeloma Forum registry ...
タイトルとURLをコピーしました